MAGNIFI
LIVE

Serial Number

90361746

Owner

Sensyne Health Group Limited

Attorney

John Mueller

Filing Date

Dec 6, 2020

Add to watchlist:

No watchlists yet
View on USPTO

MAGNIFI Trademark

Serial Number: 90361746 • Registration: 6830237

MAGNIFI is a trademark filed by Sensyne Health Group Limited on December 6, 2020. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Sensyne Health Group Limited (26 trademarks)

Schrödinger Building
Oxford, Oxfordshire OX44GE , GB

Entity Type: 99

Trademark Details

Filing Date

December 6, 2020

Registration Date

August 30, 2022

Published for Opposition

June 14, 2022

Goods & Services

Diagnostic test readers being diagnostic apparatus for testing human samples for the detection of disease in the form of a downloadable software-enabled mobile phone; Diagnostic test readers being diagnostic apparatus for testing human samples for the detection of disease in the form of a downloadable software-enabled desktop computer camera; lateral flow immunoassay readers in the form of a downloadable software-enabled mobile phone; lateral flow immunoassay readers in the form of a downloadable software-enabled desktop computer camera; downloadable computer software for use in relation to desktop computers, laptops, mobile phones, personal media players, personal digital assistants and handheld mobile computers for use in relation to diagnostic test readers and lateral flow immunoassay readers for the purposes of improving the accuracy of the diagnostic test result for the detection of disease; downloadable computer application software for use in relation to diagnostic test readers and lateral flow immunoassay readers and which, in particular, aids users in how to operate the reader and take a reading and which provides a test result to the user and healthcare provider

Software as a service (SAAS) services featuring software for use in relation to desktop computers, laptops, mobile phones, personal media players, personal digital assistants and handheld mobile computers for the purposes of improving the accuracy of the diagnostic test result performed by diagnostic test readers and lateral flow immunoassay readers for the detection of disease; application software as a service (SAAS) services featuring software for use in relation to diagnostic test readers and lateral flow immunoassay readers and which, in particular, aids users in how to operate the reader and take a reading and which provides a test result to the user and healthcare provider

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 5, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 5, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 5, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 5, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 5, 2025 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 30, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 14, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 14, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 25, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 12, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 14, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 14, 2022 GNFN
FINAL REFUSAL E-MAILED
Jan 14, 2022 GNFR
FINAL REFUSAL WRITTEN
Jan 14, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 8, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 8, 2021 CRFA
ASSIGNED TO LIE
Dec 6, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 1, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 2, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 2, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 2, 2021 CNRT
ASSIGNED TO EXAMINER
May 20, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 11, 2021 NWOS
NEW APPLICATION ENTERED
Dec 9, 2020 NWAP